{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T00:30:33Z","timestamp":1793406633637,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":64,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.gastha.2026.100920","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T16:38:35Z","timestamp":1773333515000},"page":"100920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Oral Vancomycin Is an Effective Therapy in Adult Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2337-0480","authenticated-orcid":false,"given":"Siri A.","family":"Urquhart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prajith Raj","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunanda V.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Raffals","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Edward V.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Bruining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos N.","family":"Lazaridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana G.","family":"Hashash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina Y.","family":"Ha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William S.","family":"Harmsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0775-4385","authenticated-orcid":false,"given":"Nayantara","family":"Coelho-Prabhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.gastha.2026.100920_bib1","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.gastha.2026.100920_bib2","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/apt.70303","article-title":"Primary sclerosing cholangitis in the absence of inflammatory bowel disease increases the risk of colorectal cancer: a multi-centre propensity score matched analysis","volume":"62","author":"Alsakarneh","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.gastha.2026.100920_bib3","first-page":"107","article-title":"All you need to know about the overlap between primary sclerosing cholangitis and inflammatory bowel disease","volume":"38","author":"Sleiman","year":"2025","journal-title":"Ann Gastroenterol"},{"issue":"4","key":"10.1016\/j.gastha.2026.100920_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11894-018-0620-2","article-title":"The IBD and PSC phenotypes of PSC-IBD","volume":"20","author":"Ricciuto","year":"2018","journal-title":"Curr Gastroenterol Rep"},{"issue":"1","key":"10.1016\/j.gastha.2026.100920_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1136\/gut.2004.046615","article-title":"PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis","volume":"54","author":"Loftus","year":"2005","journal-title":"Gut"},{"issue":"21","key":"10.1016\/j.gastha.2026.100920_bib6","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.3748\/wjg.v26.i21.2768","article-title":"Gut microbiome in primary sclerosing cholangitis: a review","volume":"26","author":"Little","year":"2020","journal-title":"World J Gastroenterol"},{"issue":"4","key":"10.1016\/j.gastha.2026.100920_bib7","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","article-title":"The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls","volume":"66","author":"Kummen","year":"2017","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.gastha.2026.100920_bib8","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/apt.14540","article-title":"Review article: the evidence that vancomycin is a therapeutic option for primary sclerosing cholangitis","volume":"47","author":"Damman","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.gastha.2026.100920_bib9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1093\/gastro\/goab004","article-title":"Oral vancomycin in the treatment of primary sclerosing cholangitis-associated pouchitis","volume":"9","author":"Shen","year":"2021","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"4","key":"10.1016\/j.gastha.2026.100920_bib10","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1007\/s10620-023-07826-3","article-title":"Besting the biologics: vancomycin monotherapy for ulcerative colitis management in patients with primary sclerosing cholangitis","volume":"68","author":"Ahmed","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.gastha.2026.100920_bib11","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10875-012-9801-1","article-title":"Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis","volume":"33","author":"Abarbanel","year":"2013","journal-title":"J Clin Immunol"},{"issue":"3","key":"10.1016\/j.gastha.2026.100920_bib12","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/hep.31560","article-title":"Oral vancomycin, ursodeoxycholic acid, or no therapy for pediatric primary sclerosing cholangitis: a matched analysis","volume":"73","author":"Deneau","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.gastha.2026.100920_bib13","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1055\/s-0039-1688501","article-title":"Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis","volume":"39","author":"Shah","year":"2019","journal-title":"Semin Liver Dis"},{"issue":"8","key":"10.1016\/j.gastha.2026.100920_bib14","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/00365521.2020.1787501","article-title":"Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis","volume":"55","author":"Ali","year":"2020","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastha.2026.100920_bib15","article-title":"Successful treatment of recurrent primary sclerosing cholangitis after orthotopic liver transplantation with oral vancomycin","volume":"2013","author":"Davies","year":"2013","journal-title":"Case Rep Transplant"},{"issue":"6","key":"10.1016\/j.gastha.2026.100920_bib16","doi-asserted-by":"crossref","first-page":"E174","DOI":"10.1097\/HEP.0000000000000304","article-title":"Letter to the Editor: insurance should cover vancomycin for primary sclerosing cholangitis","volume":"77","author":"Ali","year":"2023","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.gastha.2026.100920_bib17","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/apt.17990","article-title":"Editorial: is it time to include oral vancomycin in therapeutic guidelines for primary sclerosing cholangitis-associated inflammatory bowel disease?","volume":"59","author":"Shah","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.gastha.2026.100920_bib18","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/apt.17936","article-title":"Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): a matched analysis from the Paediatric PSC Consortium","volume":"59","author":"Ricciuto","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.gastha.2026.100920_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s12328-020-01272-8","article-title":"The role of oral vancomycin in inducing remission for biologic-experienced ulcerative colitis with concomitant primary sclerosing cholangitis and liver transplantation","volume":"14","author":"Rahman","year":"2021","journal-title":"Clin J Gastroenterol"},{"issue":"2","key":"10.1016\/j.gastha.2026.100920_bib20","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1007\/s12328-020-01296-0","article-title":"Successful response of primary sclerosing cholangitis and associated ulcerative colitis to oral vancomycin may depend on brand and personalized dose: report in an adolescent","volume":"14","author":"Buness","year":"2021","journal-title":"Clin J Gastroenterol"},{"issue":"5","key":"10.1016\/j.gastha.2026.100920_bib21","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/ibd\/izad040","article-title":"Oral Vancomycin induced and maintained clinical and endoscopic remission in ulcerative colitis and primary sclerosing cholangitis post-liver transplantation","volume":"29","author":"Almomen","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"5","key":"10.1016\/j.gastha.2026.100920_bib22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12664-022-01286-9","article-title":"How frequent are vancomycin-resistant enterococci in patients with primary sclerosing cholangitis and ulcerative colitis treated with oral vancomycin?","volume":"41","author":"Shah","year":"2022","journal-title":"Indian J Gastroenterol"},{"issue":"7","key":"10.1016\/j.gastha.2026.100920_bib23","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1093\/ibd\/izz027","article-title":"Oral vancomycin induces and maintains remission of ulcerative colitis in the subset of patients with associated primary sclerosing cholangitis","volume":"25","author":"Dao","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.gastha.2026.100920_bib24","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/gutjnl-2018-316599","article-title":"Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis-ulcerative colitis","volume":"68","author":"Tan","year":"2019","journal-title":"Gut"},{"issue":"10","key":"10.1016\/j.gastha.2026.100920_bib25","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1097\/MEG.0000000000001223","article-title":"Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis","volume":"30","author":"de Chambrun","year":"2018","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.gastha.2026.100920_bib26","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.gastha.2026.100920_bib27","first-page":"409","article-title":"Oral vancomycin is associated with less therapy intensification in adults with symptomatic inflammatory bowel disease and underlying primary sclerosing cholangitis","volume":"38","author":"Kulkarni","year":"2025","journal-title":"Ann Gastroenterol"},{"issue":"2","key":"10.1016\/j.gastha.2026.100920_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjae189","article-title":"Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures","volume":"19","author":"Quraishi","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastha.2026.100920_bib29","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1093\/ibd\/izaf117","article-title":"Oral vancomycin as an emerging therapy for inflammatory pouch conditions associated with primary sclerosing cholangitis","volume":"31","author":"Dunleavy","year":"2025","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"10.1016\/j.gastha.2026.100920_bib30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000544161","article-title":"Vancomycin therapy for induction and maintenance of remission in a patient with refractory ulcerative colitis and primary sclerosing cholangitis: a case report and literature review","volume":"19","author":"Lang","year":"2025","journal-title":"Case Rep Gastroenterol"},{"key":"10.1016\/j.gastha.2026.100920_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241312766","article-title":"Effectiveness and safety of oral vancomycin for the treatment of inflammatory bowel disease associated with primary sclerosing cholangitis: a systematic review and pooled analysis","volume":"18","author":"Sannaa","year":"2025","journal-title":"Ther Adv Gastroenterol"},{"issue":"7","key":"10.1016\/j.gastha.2026.100920_bib32","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/ibd\/izae257","article-title":"The effectiveness of oral vancomycin on inflammatory bowel disease in patients with primary sclerosing cholangitis: a systematic review","volume":"31","author":"Arbabzada","year":"2025","journal-title":"Inflamm Bowel Dis"}],"updated-by":[{"DOI":"10.1016\/j.gastha.2026.101021","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000}},{"DOI":"10.1016\/j.gastha.2026.101021","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000}}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326000415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326000415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T23:45:50Z","timestamp":1793403950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572326000415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2772572326000415"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2026.100920","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral Vancomycin Is an Effective Therapy in Adult Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2026.100920","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}],"article-number":"100920"}}